Further evidence of this TXNDC5 tumorigenic action was obtained when researchers showed that its inhibition by shRNA administration reduced tumor volume and weight [8] and decreased growth and invasive potential [4], a finding that indicates that TXNDC5 could be used as a biomarker and therapeutic target for cancer treatment. The gene discussed is TXNDC5; the disease is neoplasm.